| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/05/2012 | US20120003257 Recombinant avian infectious coryza vaccine and process for preparing same |
| 01/05/2012 | US20120003256 Tuberculosis antigens, immunogenic compositions, diagnostics and methods related to the same |
| 01/05/2012 | US20120003255 Flavivirus host-range mutations and uses thereof |
| 01/05/2012 | US20120003254 Breast Cancer Vaccine |
| 01/05/2012 | US20120003253 C1orf59 peptides and vaccines including the same |
| 01/05/2012 | US20120003252 Isoforms of human somatostatin receptor type 5 produced by alternative processing and oligo-nucleotide pairs for detection thereof by pcr |
| 01/05/2012 | US20120003251 Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes |
| 01/05/2012 | US20120003250 Pharmaceutical composition with immunomodulating function |
| 01/05/2012 | US20120003249 Immuno-molecules containing viral proteins, compositions thereof and methods of using |
| 01/05/2012 | US20120003248 Monomethylvaline compounds capable of conjugation to ligands |
| 01/05/2012 | US20120003247 Monomethylvaline compounds capable of conjugation to ligands |
| 01/05/2012 | US20120003246 Novel composition and methods for the treatment of psoriasis |
| 01/05/2012 | US20120003245 Anti-cobra toxin antibody fragments and method of producing a vhh library |
| 01/05/2012 | US20120003244 Methods for apcdd1 mediated regulation of hair growth and pigmentation and mutants thereof |
| 01/05/2012 | US20120003243 Yeast ectopically expressing abnormally processed proteins and uses therefor |
| 01/05/2012 | US20120003242 Modulating pdx-1 with pcif1, methods and uses thereof |
| 01/05/2012 | US20120003241 Vaccine against botulism |
| 01/05/2012 | US20120003240 Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (III) |
| 01/05/2012 | US20120003239 Enterovirus Vaccines for Preventing and Treating Type 1 Diabetes (II) |
| 01/05/2012 | US20120003238 Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (I) |
| 01/05/2012 | US20120003237 Wise binding agents and epitopes |
| 01/05/2012 | US20120003236 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| 01/05/2012 | US20120003235 Anti-lymphotoxin antibodies |
| 01/05/2012 | US20120003234 Osteoarthritis treatment |
| 01/05/2012 | US20120003233 Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
| 01/05/2012 | US20120003232 Use of antibodies for the vaccination against cancer |
| 01/05/2012 | US20120003231 Cell surface molecule mediating cell adhesion and signal transmission |
| 01/05/2012 | US20120003230 Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| 01/05/2012 | US20120003229 Modulators of cytokine mediated signalling pathways and integrin alphavbeta3 receptor antagonists for combination therapy |
| 01/05/2012 | US20120003228 Methods for predicting autoimmune disease risk |
| 01/05/2012 | US20120003227 Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
| 01/05/2012 | US20120003226 Methods for treating or preventing il-1beta related diseases |
| 01/05/2012 | US20120003225 Autoantibodies in the detection and treatment of cancer |
| 01/05/2012 | US20120003224 ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 |
| 01/05/2012 | US20120003223 Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| 01/05/2012 | US20120003222 Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same |
| 01/05/2012 | US20120003221 Human serum albumin linkers and conjugates thereof |
| 01/05/2012 | US20120003220 B7-DC Variants |
| 01/05/2012 | US20120003219 Compositions and Methods to Treat Bone Related Disorders |
| 01/05/2012 | US20120003218 Antagonists of actriib and uses for increasing red blood cell levels |
| 01/05/2012 | US20120003217 Herceptin® aduvant therapy |
| 01/05/2012 | US20120003216 Fgf21 mutants and uses thereof |
| 01/05/2012 | US20120003215 Pyrazolo[1,5-a]pyrimidines for antiviral treatment |
| 01/05/2012 | US20120003214 Binding Moieties Based On Shark IgNAR Domains |
| 01/05/2012 | US20120003213 Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity |
| 01/05/2012 | US20120003212 Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8 associated disorders |
| 01/05/2012 | US20120003211 Immunoglobulins with reduced aggregation |
| 01/05/2012 | US20120003210 NEONATAL Fc RECEPTOR (FcRn)- BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| 01/05/2012 | US20120003209 Methods and kits used in identifying glioblastoma |
| 01/05/2012 | US20120003208 Compositions and methods for modulating vascular development |
| 01/05/2012 | US20120003207 Methods and compositions for modulating proline levels |
| 01/05/2012 | US20120003184 Sodium salt of 5-cyclopropyl-2-benzoic acid as dhodh inhibitor |
| 01/05/2012 | US20120003183 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
| 01/05/2012 | US20120003181 Novel Retinoid Inducible Factor and Uses Thereof |
| 01/05/2012 | US20120003180 Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function |
| 01/05/2012 | US20120003179 Anti-ctla-4 and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| 01/05/2012 | US20120003157 Use of anti-90k monoclonal antibodies for the prevention and treatment of tumors and metastases thereof |
| 01/05/2012 | US20120003150 Therapeutic ribonucleases |
| 01/05/2012 | US20120003149 Novel monoclonal antibody, and use thereof |
| 01/05/2012 | CA2805548A1 The role of fragile x mental retardation gene and protein in cancer metastasis |
| 01/05/2012 | CA2804149A1 Nanoemulsion vaccines |
| 01/05/2012 | CA2803998A1 Antibody formulations |
| 01/05/2012 | CA2803989A1 Env trimer immunogens |
| 01/05/2012 | CA2803444A1 Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-l-like receptor ligand or a nod-like receptor ligand to enhance the innate immune response |
| 01/05/2012 | CA2803298A1 Compositions and methods related to protein a (spa) variants |
| 01/05/2012 | CA2799472A1 Treatment of vascularized pigment epithelial detachment with anti-vegf therapy |
| 01/04/2012 | EP2402756A2 Agonist anti-trkC antibodies and methods using same |
| 01/04/2012 | EP2402451A2 Method for stabilizing an DNA insert in a recombinant vaccinia vector |
| 01/04/2012 | EP2402447A1 Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment |
| 01/04/2012 | EP2402445A1 Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
| 01/04/2012 | EP2402373A2 Anti-EphB4 Antibodies and Methods Using Same |
| 01/04/2012 | EP2402372A2 Therapeutic agent |
| 01/04/2012 | EP2402365A1 Crystal structure of amino terminal portion of influenza virus polymerase pa subunit and use thereof |
| 01/04/2012 | EP2402359A1 Recombinant protective protein from streptococcus pneumoniae |
| 01/04/2012 | EP2402033A1 Cell adhesion inhibitor and use thereof |
| 01/04/2012 | EP2402032A1 Immunogenic composition |
| 01/04/2012 | EP2402031A1 Immunologic adjuvant composition and use thereof |
| 01/04/2012 | EP2402030A1 Linear IgE peptide epitopes of celery allergen api 1 |
| 01/04/2012 | EP2402029A1 Enterovirus vaccines for preventing or treating type 1 diabetes (III) |
| 01/04/2012 | EP2402028A1 Enterovirus vaccines for preventing and treating type 1 diabetes (II) |
| 01/04/2012 | EP2402027A1 Enterovirus vaccines for preventing or treating type 1 diabetes (I) |
| 01/04/2012 | EP2402026A2 Method for isolating hepatitis C virus peptides |
| 01/04/2012 | EP2402025A2 Vaccine |
| 01/04/2012 | EP2402024A1 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
| 01/04/2012 | EP2402023A1 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
| 01/04/2012 | EP2402022A2 Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis |
| 01/04/2012 | EP2402019A1 Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues |
| 01/04/2012 | EP2402013A1 Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist |
| 01/04/2012 | EP2401302A1 Antibodies containing therapeutic tpo/epo mimetic peptides |
| 01/04/2012 | EP2401300A1 ANTI-C mX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES |
| 01/04/2012 | EP2401299A1 Anti-icam-1 antibody, uses and methods |
| 01/04/2012 | EP2400985A2 Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| 01/04/2012 | EP2400983A1 Use of anti-90k monoclonal antibodies for the prevention and treatment of tumors and metastases thereof |
| 01/04/2012 | EP2400982A1 Multiple antigen delivery system using hepatitis e virus-like particle |
| 01/04/2012 | EP2400981A1 Humanized platelet activating factor antibody design using anti-lipid antibody templates |
| 01/04/2012 | EP2182923B1 Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof |
| 01/04/2012 | EP1951299B1 Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| 01/04/2012 | EP1898948B1 Polyinosinic acid-polycytidylic acid-based adjuvant |
| 01/04/2012 | EP1080107B1 Novel peptides which represent the epitopes of the human herpes virus type 8 |
| 01/04/2012 | EP0914142B9 Peptides with increased binding affinity for at least three hla-a3-like molecules |